Combination antiretroviral therapy and incidence of AIDS-related malignancies. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Combination antiretroviral therapy and incidence of AIDS-related malignancies.

J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S23-6. Unique Identifier : AIDSLINE MED/99357283
Buchbinder SP; Holmberg SD; Scheer S; Colfax G; O'Malley P; Vittinghoff E; HIV Research Section, San Francisco Department of Public Health,; California, USA.

Abstract: We evaluated recent trends in the incidence of AIDS-related malignancies using Cox proportional hazards analysis in 622 men with well-characterized dates of HIV seroconversion in the San Francisco City Clinic cohort. By the end of 1996, 182 men had been diagnosed with Kaposi's sarcoma (KS), and 45 men had been diagnosed with lymphoma. The incidence of KS dropped from 3.5 to 0 per 100 person-years between 1993 through 1995 and 1996 (p = .07), whereas lymphoma incidence remained stable between these periods (1.4-1.8, p = .2). Combination antiretroviral therapy increased from 13% to 23% in 1993 through 1995 to 49% in 1996 and 79% in 1997. The decline in KS cannot be explained by earlier declines in HIV incidence, and concurrent increases in antiretroviral therapy suggests that control of viral replication may lead to a direct or indirect effect on KS pathogenesis. Failure to see such a trend for AIDS-related lymphoma may reflect inadequate follow-up time after widespread use of therapy or a need to treat earlier in the course of HIV infection to prevent HIV-associated lymphomagenesis.
Keywords: JOURNAL ARTICLE *Anti-HIV Agents/ADMINISTRATION & DOSAGE AIDS-Related Opportunistic Infections/*EPIDEMIOLOGY Central Nervous System Neoplasms/EPIDEMIOLOGY Drug Therapy, Combination Human Incidence Lymphoma/*EPIDEMIOLOGY Lymphoma, AIDS-Related/EPIDEMIOLOGY Lymphoma, Non-Hodgkin/EPIDEMIOLOGY Male Prevalence Support, U.S. Gov't, P.H.S.KWDjournalarticleKWDanti-hivagents/administration&dosageaids-relatedopportunisticinfections/KWDepidemiologycentralnervoussystemneoplasms/epidemiologydrugtherapy,combinationhumanincidencelymphoma/KWDepidemiologylymphoma,aids-related/epidemiologylymphoma,non-hodgkin/epidemiologymaleprevalencesupport,uKWDsKWDgov't,pKWDhKWDs
991030
A99A0171

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .